Relay Therapeutics (RLAY) Stifel 2024 Healthcare Conference summary

Portfolio evolution and R&D progress

• Announced two innovative programs for Fabry and NRAS molecules, advancing preclinical work with plans to enter the clinic next year.

• Expanded PI3K alpha franchise, including plans to bring 2608 into genetic disease vascular malformations.

• Demonstrated continued productivity in targeting difficult molecules and evolving the pipeline.

2608 clinical data and Phase 3 trial plans

• 2608 showed highest PFS, ORR, and CBR to date in PIK3CA-mutated breast cancer when combined with fulvestrant.

• Phase 3 trial will compare 2608 plus fulvestrant to capivasertib plus fulvestrant in second-line patients.

• Phase 1b data in a heavily pretreated population showed 9.2 months median PFS, supporting confidence for Phase 3 success.

• Efficacy appears maximized above IC80 threshold, with no further gains at higher doses.

Comparator and regulatory strategy

• Capivasertib chosen as comparator due to strong physician preference and superior commercial performance over Piqray.

• Regulatory discussions are a top priority, aiming for rapid trial initiation and public disclosure of outcomes.